Girish Gudi

695 citations

31 papers · 475 indexed · h-index 11

Co-authors: Yacine Salhi Jonathan Back G. Wolff Emma Guttman‐Yassky Yeriel Estrada Ana B. Pavel Neelima Khairatkar-Joshi Lisa Zhou
Topics: Phosphodiesterase function and regulation (6 papers)Dermatology and Skin Diseases (5 papers)Pharmacogenetics and Drug Metabolism (5 papers)
Cited by: Immunology and Allergy Dermatology Sensory Systems
Journals: SHILAP Revista de lepidopterologíaBlood Pain
Partner nations: India United States Switzerland

In The Last Decade

Girish Gudi

30 papers receiving 466 citations

Peers

Countries citing papers authored by Girish Gudi

Since Specialization

Citations

This map shows the geographic impact of Girish Gudi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Girish Gudi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Girish Gudi more than expected).

Fields of papers citing papers by Girish Gudi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Girish Gudi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Girish Gudi. The network helps show where Girish Gudi may publish in the future.

Co-authorship network of co-authors of Girish Gudi

This figure shows the co-authorship network connecting the top 25 collaborators of Girish Gudi. A scholar is included among the top collaborators of Girish Gudi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Girish Gudi. Girish Gudi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	472 Telazorlimab in atopic dermatitis: Phase 2b study shows improvement at 16 weeks 2021 ·Journal of Investigative Dermatology ·(unknown),(unknown),(unknown),Girish Gudi,Yacine Salhi,(unknown),Kinesh Changela,Neelufar Mozaffarian	4
2	Single-step Protein A and Protein G avidity purification methods to support bispecific antibody discovery and development 2019 ·mAbs ·(unknown),Paul Wassmann,Thierry Monney,(unknown),(unknown),(unknown),Daniel Ayoub,(unknown),Girish Gudi,(unknown)	19
3	GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis 2019 ·Journal of Allergy and Clinical Immunology ·Emma Guttman‐Yassky,Ana B. Pavel,Lisa Zhou,Yeriel Estrada,Ning Zhang,Hui Xu,Xiangyu Peng,Huei‐Chi Wen,(unknown),Girish Gudi,(unknown),Hui Fang,Yacine Salhi,Jonathan Back,Venkateshwar A. Reddy,Robert Bissonnette,Catherine Maari,Fred Grossman,G. Wolff	160
4	An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions 2019 ·Clinical Pharmacokinetics ·Shashank Joshi,Girish Gudi,(unknown),Monika Tandon,Vikas Joshi,(unknown),Hanmant Barkate,(unknown),(unknown),Waseem Siddique	3
5	Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[d]imidazole series – Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2 2018 ·Bioorganic & Medicinal Chemistry Letters ·Muthukaman Nagarajan,(unknown),(unknown),(unknown),(unknown),Mahamadhanif S. Shaikh,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Abhay Kulkarni,(unknown),Satyawan Jadhav,(unknown),Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	5
6	1094 Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis 2018 ·Journal of Investigative Dermatology ·Girish Gudi,(unknown),(unknown),(unknown),Jonathan Back,Hua Fang,Yacine Salhi,(unknown),(unknown)	3
7	GRC 27864, novel, microsomal prostaglandin E synthase-1 enzyme inhibitor: phase 1 study to evaluate safety, PK and biomarkers in healthy, adult subjects 2018 ·Osteoarthritis and Cartilage ·Shilpa Sant,Monika Tandon,(unknown),Girish Gudi,(unknown),(unknown),(unknown),(unknown)	11
8	Discovery of 5-(2-chloro-4′-(1H-imidazol-1-yl)-[1,1′-biphenyl]-4-yl)-1H-tetrazole as potent and orally efficacious S-nitrosoglutathione reductase (GSNOR) inhibitors for the potential treatment of COPD 2018 ·Bioorganic & Medicinal Chemistry Letters ·Muthukaman Nagarajan,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Samitabh Chakraborti,(unknown),(unknown),Abhay Kulkarni,(unknown),Satyawan Jadhav,Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	2
9	Discovery of furan and dihydrofuran-fused tricyclic benzo[d]imidazole derivatives as potent and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-1 2017 ·Bioorganic & Medicinal Chemistry Letters ·Muthukaman Nagarajan,(unknown),(unknown),(unknown),(unknown),Mahamadhanif S. Shaikh,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Abhay Kulkarni,(unknown),Satyawan Jadhav,(unknown),Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	5
10	Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model 2017 ·Bioorganic & Medicinal Chemistry Letters ·Muthukaman Nagarajan,(unknown),Mahamadhanif S. Shaikh,(unknown),(unknown),(unknown),(unknown),Lakshminarayana Narayana,(unknown),(unknown),(unknown),(unknown),Abhay Kulkarni,(unknown),Satyawan Jadhav,Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	6
11	Discovery of 2-((2-chloro-6-fluorophenyl)amino)-N-(3-fluoro-5-(trifluoromethyl)phenyl)-1-methyl-7,8-dihydro-1H-[1,4]dioxino[2′,3′:3,4]benzo[1,2-d]imidazole-5-carboxamide as potent, selective and efficacious microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor 2016 ·Bioorganic & Medicinal Chemistry Letters ·Muthukaman Nagarajan,(unknown),(unknown),(unknown),(unknown),(unknown),Mahamadhanif S. Shaikh,(unknown),(unknown),(unknown),Abhay Kulkarni,Satyawan Jadhav,(unknown),Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	8
12	Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists 2015 ·Journal of Medicinal Chemistry ·(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Neelima Khairatkar-Joshi,Malini Bajpai,(unknown),(unknown),Srinivas Gullapalli,P. K. Gupta,Girish Gudi,Satyawan Jadhav,(unknown),Abraham Thomas	10
13	Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I 2014 ·Bioorganic & Medicinal Chemistry Letters ·Sanjib Das,(unknown),(unknown),Neelima Khairatkar-Joshi,Malini Bajpai,(unknown),(unknown),Girish Gudi,(unknown),(unknown),Satyawan Jadhav,Abraham Thomas	8
14	Effect of commonly used organic solvents on Aldehyde oxidase-mediated Vanillin, Phthalazine and Methotrexate oxidation in human, rat and mouse liver subcellular fractions 2014 ·Xenobiotica ·(unknown),(unknown),Girish Gudi	16
15	Utility of a column-switching LC/MS/MS method in cytochrome P450 inhibition assays using human liver microsomes 2013 ·Drug metabolism and drug interactions ·(unknown),(unknown),(unknown),Girish Gudi	3
16	Discovery of benzo[d]imidazo[5,1-b]thiazole as a new class of phosphodiesterase 10A inhibitors 2013 ·Bioorganic & Medicinal Chemistry Letters ·Abhisek Banerjee,Lakshminarayana Narayana,(unknown),(unknown),(unknown),Srinivas Gullapalli,Hemant Kumar,Sandeep Vasant More,Malini Bajpai,(unknown),Satyawan Jadhav,Girish Gudi,Neelima Khairatkar-Joshi,(unknown),(unknown),Laxmikant A. Gharat	23
17	FLUORESCENT PROBE BASED CYP INHIBITION ASSAY: A HIGH THROUGHPUT TOOL FOR EARLY DRUG DISCOVERY SCREENING 2013 ·(unknown),(unknown),(unknown),Ginpreet Kaur,Girish Gudi	7
18	Synthesis and pharmacological evaluation of novel N-aryl-3,4-dihydro-1′H-spiro[chromene-2,4′-piperidine]-1′-carboxamides as TRPM8 antagonists 2013 ·Bioorganic & Medicinal Chemistry ·Sachin S. Chaudhari,(unknown),Neelima Khairatkar-Joshi,Indranil Mukhopadhyay,(unknown),(unknown),Shobha Rao,(unknown),(unknown),(unknown),Girish Gudi,(unknown),Abraham Thomas	25
19	Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model 2012 ·Bioorganic & Medicinal Chemistry Letters ·Abhisek Banerjee,S. D. Patil,(unknown),Srinivas Gullapalli,P. K. Gupta,(unknown),(unknown),Malini Bajpai,(unknown),Girish Gudi,Neelima Khairatkar-Joshi,Laxmikant A. Gharat	30
20	The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot 2012 ·Recent Patents on Inflammation & Allergy Drug Discovery ·(unknown),Ginpreet Kaur,Girish Gudi,Veeranjaneyulu Addepalli	2

About Girish Gudi

Girish Gudi is a scholar working on Pharmacology, Pharmacology and Dermatology, having authored 31 papers that have together received 475 indexed citations. Recurring topics across this work include Phosphodiesterase function and regulation (6 papers), Dermatology and Skin Diseases (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). The work is most often cited by research in Immunology and Allergy (139 citations), Dermatology (168 citations) and Sensory Systems (34 citations). Girish Gudi has collaborated with scholars based in India, United States and Switzerland. Frequent co-authors include Yacine Salhi, Jonathan Back, G. Wolff, Emma Guttman‐Yassky, Yeriel Estrada, Ana B. Pavel, Neelima Khairatkar-Joshi, Lisa Zhou, Laxmikant A. Gharat and Ning Zhang. Their work appears in journals such as SHILAP Revista de lepidopterología, Blood and Pain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact